For up to date information, videos and support resources on COVID-19 from the Psychiatry Academy, click here.
Due to the Coronavirus pandemic, our staff and faculty will be working remotely.
Please email us with any questions at or call 866-644-7792 and leave a message.


Chabner, Bruce, MD

Clinical Director, Emeritus, and Allen Distinguished Investigator
Massachusetts General Hospital


For the past 48 years I have devoted myself to a career in cancer research and drug development. I directed the Drug Development Program and the clinical trials efforts of the National Cancer Institute, as Director of the Division of Cancer Treatment, for 14 years (1981-1995), and have designed, participated in, and reported clinical and laboratory studies of new agents, including maytansine, folate analogues, paclitaxel, fludarabine, and Yondelis. Twenty years ago I moved to Harvard Medical School and the Massachusetts General Hospital, where I was Chief of the Division of Hematology/Oncology from 1995-2006 and Clinical Director of the MGH Cancer Center from 1995-2010. For the past 15 years I have had a leadership role in the Dana Farber Harvard Cancer Center, as Associate Director of Clinical Sciences from 2000-2011, and Co-director of the Translational Pharmacology and Experimental Therapeutics Program, 2000-present. I am currently the Clinical Director, Emeritus at the MGH Cancer Center. I author the standard textbook on the pharmacology of anticancer drugs (The Principles and Practice of Cancer Chemotherapy and Biotherapy) now in its 5th edition, and co-edited the latest edition of the standard medical textbook on pharmacology (Goodman and Gilman's Pharmacological Basis of Therapeutics). Many of the drugs I have studied, most particularly fludarabine, cytosine arabinoside, and antifolates, remain standard agents, but my interests have turned toward the strategic and regulatory issues related to development of targeted drugs. Throughout this career I have remained active as a clinician, teacher, and mentor of academic physician-investigators in the cancer field. I have served on the Internal Advisory Board for The Lung Spore grant as well as for The Brain Tumor and GI Spore grants over the past decade, and have been particularly active in reviewing developmental grant projects.

My sustained involvement in cutting edge oncology research qualifies me well to contribute to the scientific development of this project focused the immunology of HIV-associated cancers in Botswana has been a major focus of my work for the past 4 years.